Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management |
| |
Authors: | Leitersdorf E |
| |
Institution: | Centre for Research, Prevention, and Treatment of Atherosclerosis, Hadassah University Hospital, Jerusalem, Israel. |
| |
Abstract: | Many individuals throughout Europe have risk factors for coronary heart disease (CHD) and are non-compliant with recommended treatments, despite guidelines for the reduction of low-density lipoprotein cholesterol (LDL-C) and the prevention of CHD. Significant numbers who should receive pharmacotherapy for hypercholesterolaemia do not, and one-third of treated patients do not achieve recommended target LDL-C levels. Optimum doses of statins, which have demonstrated undisputed efficacy in the treatment of hypercholesterolaemia in clinical trials, are seldom used; the inconvenience of dosage adjustments and safety concerns, particularly myalgia, may constitute obstacles to their optimal use for LDL-C reduction in clinical practice. Ezetimibe is the first selective cholesterol absorption inhibitor that has demonstrated clinical benefits when used as either monotherapy or in combination with other lipid-modifying agents. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|